Clinical Trials on Colitis in Japan

Total 100 results

Showa Inan General Hospital

Recruiting

Association Between LRG and Histologic Remission in Ulcerative Colitis

Ulcerative Colitis in Histologic Remission

Japan
Kyowa Kirin Co., Ltd.

Completed

A Phase 1 Study of KHK4083 in Healthy Volunteers and Subjects With Ulcerative Colitis

Healthy Men and Subjects With Ulcerative Colitis

Japan
Takeda

Active, not recruiting

Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Ulcerative Colitis]

Ulcerative Colitis

Japan
Kyoto University, Graduate School of Medicine
National Institute of Biomedical Innovation

Terminated

Therapeutic Study of ONO-4819CD for Ulcerative Colitis

Ulcerative Colitis

Japan
Pfizer

Completed

Xeljanz Special Investigation for Long-term Use in UC Patients

Ulcerative Colitis

Japan
Pfizer

Completed

Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)

Crohn's Disease | Ulcerative Colitis

Japan
Kyorin Pharmaceutical Co.,Ltd

Completed

Observational Study in the Management of Ulcerative Colitis With Oral 5-ASA

Ulcerative Colitis

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis

Pediatric Ulcerative Colitis

Japan
Kissei Pharmaceutical Co., Ltd.

Recruiting

An Early Phase 2 Clinical Study of KSP-0243

Colitis, Ulcerative

Japan
Astellas Pharma Inc

Completed

Tacrolimus (FK506) P-III, Open-label Study in Refractory Ulcerative Colitis Patients

Ulcerative Colitis

Japan
Astellas Pharma Inc

Completed

Tacrolimus (FK506) Study in Moderate to Severe Refractory Ulcerative Colitis Patients

Ulcerative Colitis

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis

Colitis, Ulcerative

Japan
Asahi Kasei Medical Co., Ltd.
Asahi Kasei Medical Europe GmbH

Terminated

A Study of Leukocytapheresis (LCAP) in Patients With Ulcerative Colitis (UC)

Ulcerative Colitis

United Kingdom, Japan, Germany, Sweden, Israel, Czech Republic
Pfizer

Completed

A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis

Arthritis, Rheumatoid | Psoriasis | Crohn Disease | Colitis, Ulcerative

Japan
Sanofi

Completed

Japanese Study Evaluating the Effects of Telithromycin in Children With Acute Otitis Media

Otitis Media

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of Symptom Improvement of Ulcerative Colitis After an Induction Dose of Ustekinumab in Japanese Clinical Practice

Ulcerative Colitis

Japan
Otsuka Pharmaceutical Co., Ltd.

Terminated

A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis

Colitis, Ulcerative

Japan
AstraZeneca

Completed

MEDI7183 Phase 2 Study in Japanese Ulcerative Colitis Patients

Ulcerative Colitis

Japan
Eli Lilly and Company

Recruiting

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON) (SHINE-ON)

Inflammatory Bowel Diseases | Crohn's Disease | Ulcerative Colitis | Ulcerative Colitis Chronic

United States, Korea, Republic of, Poland, Italy, Japan
Takeda

Recruiting

A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease

Crohn's Disease | Ulcerative Colitis

Japan
AbbVie

Active, not recruiting

Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis

Ulcerative Colitis

United States, Japan, Poland, Slovakia, Spain, United Kingdom
EA Pharma Co., Ltd.

Completed

Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis

Moderate Active Ulcerative Colitis

Japan
Amgen

Recruiting

Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

United States, Germany, Japan, Denmark, Romania, Argentina, Bulgaria, Hungary, Korea, Republic of, Mexico, Poland, Switzerland, Turkey
Pfizer
Arena is a wholly owned subsidiary of Pfizer

Recruiting

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

Ulcerative Colitis

United States, Spain, Japan, Belgium, Austria, Poland
Janssen Research & Development, LLC

Recruiting

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (QUASAR Jr)

Colitis, Ulcerative

Belgium, United States, China, Denmark, Japan, Italy, Turkey, Poland
AstraZeneca

Terminated

Open-label Extension Study of Brazikumab in Ulcerative Colitis (Expedition)

Ulcerative Colitis

Italy, United States, Taiwan, Germany, Poland, Israel, Puerto Rico, Czechia, South Africa, Japan, Korea, Republic of
AbbVie (prior sponsor, Abbott)
Eisai Co., Ltd.

Completed

A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

Japan
Eli Lilly and Company

Completed

A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC) (SHINE-1)

Ulcerative Colitis

United States, Canada, Israel, Korea, Republic of, Japan
Pfizer
Arena is a wholly owned subsidiary of Pfizer

Completed

Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN)

Ulcerative Colitis

Japan
Janssen Pharmaceutical K.K.

Completed

A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis.

Colitis, Ulcerative

Japan
Hoffmann-La Roche
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis

Moderate to Severe Ulcerative Colitis

United States, Australia, Thailand, Poland, Russian Federation, Japan, Colombia, Spain, Turkey, Romania, India, Slovakia, France, Hungary, South Africa, Belgium, Bulgaria, Germany, Italy, Mexico, Serbia, Ukraine, United Kingdom
Bristol-Myers Squibb

Completed

A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis

Crohn Disease | Ulcerative Colitis

Romania, Italy, United States, Australia, Canada, China, Germany, Hungary, Japan, Netherlands, Poland, Portugal, Russian Federation, Spain, Taiwan, United Kingdom
AbbVie

Completed

Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Australia, Austria, Belgium, Canada, Czechia, Hungary, Israel, Japan, New Zealand, Poland, Slovakia, Spain, United Kingdom
Theravance Biopharma

Terminated

Efficacy & Safety of TD-1473 in Ulcerative Colitis (RHEA)

Ulcerative Colitis (UC)

United States, Australia, Bulgaria, Canada, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Portugal, Romania, Serbia, Slovakia, South Africa, Spain, Taiwan, Ukraine
AbbVie

Completed

Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis (UC)

United States, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Netherlands, Poland, Romania, Slovakia, Spain, Switzerland, Ukraine, United Kingdom
Sanofi

Recruiting

Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis (RESOLUTE)

Colitis Ulcerative

Argentina, Chile, United States, China, Czechia, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Spain, United Kingdom
Gilead Sciences

Recruiting

Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis (PALEKONA)

Ulcerative Colitis

United States, Australia, United Kingdom, Korea, Republic of, Japan, Italy, France, Canada, Switzerland, Austria, Germany, Hungary, Poland
Bristol-Myers Squibb

Completed

Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

Korea, Republic of, United States, Australia, Hungary, Germany, Italy, United Kingdom, Czechia, Japan, Russian Federation, France, Belgium, Poland
Merck Sharp & Dohme LLC
PPD, Part of Thermo Fisher Scientific

Recruiting

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

Ulcerative Colitis

United States, Israel, Japan, Korea, Republic of, Switzerland, Chile
Eli Lilly and Company

Recruiting

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis (SHINE-2)

Ulcerative Colitis

Canada, United States, Japan, Belgium, Israel, Portugal, Korea, Republic of, France, Australia, Italy, Netherlands, Poland, Germany, United Kingdom
Theravance Biopharma

Terminated

TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study

Ulcerative Colitis (UC)

United States, Australia, Bulgaria, Canada, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Portugal, Romania, Serbia, Slovakia, South Africa, Spain, Taiwan, Ukraine
Pfizer

Terminated

A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission

Ulcerative Colitis

Spain, United States, Korea, Republic of, Serbia, Canada, Poland, Japan, France, New Zealand, South Africa, Germany, Slovakia, Hungary, Belgium, Czechia, Italy, Netherlands, Russian Federation, Ukraine, United Kingdom
AbbVie

Recruiting

Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

Ulcerative Colitis

United States, Japan, Taiwan, Spain, Korea, Republic of, Bulgaria, Italy, Poland, France, United Kingdom, Greece, New Zealand, Australia, Belgium, Israel, Hungary, Netherlands
Eli Lilly and Company

Completed

A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Australia, Netherlands, Poland, Belgium, France, Hungary, Lithuania, Canada, Czechia, Denmark, Georgia, Japan, Moldova, Republic of, Romania, United Kingdom
AbbVie

Recruiting

An Observational Study to Assess Change in Disease Activity and Adverse Events of Rinvoq in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Japan

Ulcerative Colitis

Japan
Takeda

Completed

Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis

Ulcerative Colitis

Japan
Sanofi
Regeneron Pharmaceuticals

Recruiting

A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))

Colitis Ulcerative

Argentina, Korea, Republic of, Mexico, United States, Canada, Chile, Japan, Puerto Rico, South Africa, Taiwan, Turkey
Pfizer
Arena is a wholly owned subsidiary of Pfizer

Completed

Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

Japan
AstraZeneca

Terminated

Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis (Expedition)

Ulcerative Colitis | IBD

United States, Italy, Taiwan, Korea, Republic of, Germany, Spain, Russian Federation, Japan, South Africa, Hungary, Poland, Israel, Puerto Rico, Czechia, Ukraine, United Kingdom, Canada, India, Slovakia
Pfizer

Recruiting

Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Israel, Poland, Canada, Japan, Belgium, Spain, Hungary, Finland, France, United Kingdom, Australia, Germany, Italy, Sweden, Netherlands, Slovakia

Clinical Trials on Colitis in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations